权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel differentiation therapy for AML

AML 的新型分化疗法

基本信息

批准号：
7847345
负责人：
Mukesh Kumar Agarwal
金额：
$ 0.55万
依托单位：
INVENIO THERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-06-01 至 2009-10-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7847345
关键词：
6-benzylthioinosine Acute Acute Myelocytic Leukemia Acute Promyelocytic Leukemia Adult Age Alternative Therapies Benign Biological Assay Biological Models Biology Bone Marrow Cell Culture Techniques Cell Surface Proteins Cells Cessation of life Clinical Clinical Trials Collaborations Data Development Differentiation Therapy Disease Drug Delivery Systems Drug Formulations Drug Kinetics Elderly Engraftment Ensure Exhibits Familiarity Goals Hematopathology Hematopoietic In Vitro Individual International Lead Leukemic Cell Life Malignant - descriptor Malignant Neoplasms Marketing Measures Modeling Mus Myeloid Cells Natural regeneration Nonprofit Organizations Outcome Patients Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacologic Substance Phase Preclinical Drug Development Preclinical Drug Evaluation Preparation Proliferating Public Health Receptor Signaling Reporting Research Sampling Source Therapeutic Toll-like receptors Toxic effect Treatment Protocols Tretinoin Work Xenograft Model Xenograft procedure age group cancer cell cell growth chemotherapy cytotoxicity drug development experience improved in vivo leukemia member mouse model novel novel therapeutics nucleoside analog older patient patient population pre-clinical programs public health relevance research study stem success technological innovation

项目摘要

DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults and despite advances in treatment the 5 year survival is less than 20-50% in adults and significantly lower in the elderly. The remarkable success in treating one relatively uncommon subset of AML, acute promyelocytic leukemia, with all trans-retinoic acid (ATRA) illustrates the great promise for agents with greater efficacy and less toxicity. Utilizing ATRA, the presumed cure of 75-85% of patients is possible. ATRA's remarkable success stems from the fact that AML is a disease characterized by the arrest of differentiation of immature myeloid cells. ATRA overcomes this block in differentiation by forcing leukemic cells to mature. After leukemic cells undergo terminal differentiation, they lose their ability to proliferate. The aim of this phase I project is to demonstrate the promise of a novel nucleoside analogue with potent differentiation-inducing activity for the treatment of AML. This compound will be evaluated for differentiation activity using primary patient samples in both cell culture and bone marrow engraftment mouse xenograft experiments. In addition, this promising compound will be analyzed for potential toxicities, particularly myelotoxicity. As differentiation therapies are able to treat leukemia without the necessity for overt cytotoxicity, this work has the potential to lead to a more efficacious, less toxic, and better tolerated therapy for patients with AML. PUBLIC HEALTH RELEVANCE: This project is highly relevant to public health as its main objective is to develop a novel therapy for patients with Acute Myeloid Leukemia that is both efficacious and has low toxicity. As the current AML therapeutics have low efficacy and high toxicities, there is a significant need for new therapies for AML.

描述（由申请人提供）：急性髓性白血病（AML）是成人中最常见的白血病形式之一，尽管治疗取得了进展，但成人的5年生存率低于20-50%，老年人的5年生存率明显更低。全反式维甲酸（ATRA）在治疗AML的一个相对罕见的子集，急性早幼粒细胞白血病的显着成功，说明了具有更大疗效和更低毒性的药物的巨大前景。使用ATRA，75-85%的患者的假定治愈是可能的。ATRA的显著成功源于AML是一种以未成熟骨髓细胞分化停滞为特征的疾病。ATRA通过迫使白血病细胞成熟来克服这种分化障碍。在白血病细胞经历终末分化后，它们失去了增殖能力。该I期项目的目的是证明一种具有强效分化诱导活性的新型核苷类似物用于治疗AML的前景。将在细胞培养和骨髓移植小鼠异种移植实验中使用原代患者样本评价该化合物的分化活性。此外，将分析这种有前途的化合物的潜在毒性，特别是骨髓毒性。由于分化疗法能够在不需要明显细胞毒性的情况下治疗白血病，因此这项工作有可能为AML患者带来更有效、毒性更小和耐受性更好的疗法。公共卫生相关性：该项目与公共卫生高度相关，因为其主要目标是为急性髓性白血病患者开发一种既有效又低毒的新疗法。由于目前的AML疗法具有低疗效和高毒性，因此对AML的新疗法存在显著需求。